Hashimoto, Yoshitaka http://orcid.org/0000-0002-8651-4445
Hamaguchi, Masahide http://orcid.org/0000-0002-8794-0550
Fukuda, Takuya
Ohbora, Akihiro
Kojima, Takao
Fukui, Michiaki
Article History
Received: 2 February 2017
Accepted: 26 April 2017
First Online: 16 May 2017
Compliance with ethical standards
:
: M. Fukui has received grant and research support from AstraZeneca plc, Astellas Pharma Inc., Bristol-Myers Squibb K.K., Daiichi Sankyo Co., Ltd., Eli Lilly Japan K.K., Kyowa Hakko Kirin Company Ltd., Kowa Pharmaceutical Co., Ltd., Kissei Pharmaceutical Co., Ltd., MSD K.K., Mitsubishi Tanabe Pharma Corporation, Novo Nordisk Pharma Ltd., Nippon Chemiphar Company Ltd., Sanwa Kagaku Kenkyusho Co., Ltd., Sanofi K.K., Taisho Toyama Pharmaceutical Co., Ltd., Takeda Pharmaceutical Co., Ltd., Terumo Co. The sponsors were not involved in the study design; in the collection, analysis, interpretation of data; in the writing of this manuscript; or in the decision to submit the article for publication. M. Fukui, his immediate families, and any research foundations with which they are affiliated have not received any financial payments or other benefits from any commercial entity related to the subject of this article. M. Fukui received no current funding for this study and this does not alter their adherence to all of the journal policies on sharing data and materials. The remaining authors declare that they have no competing interests.
: The study was conducted in accordance with the Declaration of Helsinki, and an independent ethics committee.
: Informed consent was obtained from all individual participants included in the study.